U.S., March 25 -- ClinicalTrials.gov registry received information related to the study (NCT07489430) titled 'DaxibotulinumtoxinA for Blepharospasm' on March 04.
Brief Summary: This study aims to provide real-world information about the duration, safety, and overall benefit of DaxibotulinumtoxinA (also called DAXI) treatment for adults living with blepharospasm (BSP), a condition that causes uncontrolled blinking or muscle spasms around the eyes, which can interfere with vision and daily activities. Specifically, it is being done to learn more about how well and how long DAXI works for treating adults with blepharospasm.
This is a single-center, open-label, single-arm study, meaning everyone in the study will receive DAXI, and both partic...